Evidence-Based Clinical Management of Advanced and Castration-Resistant Prostate Cancer - Phoenix (2018)
Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
There is a growing need for urologists to be able to effectively manage castration-resistant prostate cancer (CRPC). The AUA recently released its 2017 report on the educational needs of urologists in the area of CRPC. These findings show strong support for the AUA to influence key stakeholders in urology residency programs in order to increase the amount of exposure residents receive in this area. Additionally, the findings indicate that the AUA should continue to develop courses and educational materials specifically targeted at residents that covers the medical management of advanced prostate cancer.
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
The 2018 series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts.
All activities are complimentary.
This educational series is supported by independent educational grants from:
- Ferring Pharmaceuticals Inc.
- Genomic Health
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Medivation, Inc. a Pfizer company
- Sanofi Genzyme
- Tolmar Pharmaceuticals, Inc.
- Advanced practice providers
- This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer
At the conclusion of this activity, participants will be able to:
Practice Gap #1 (Disease State)
- Describe the natural course of advanced prostate cancer from non-metastatic to metastatic hormone-sensitive disease, with progression to the development of castration-resistant disease.
- Describe the treatment options and outcomes for newly diagnosed metastatic hormone-sensitive prostate cancer.
- Explain the implications of CRPC on the management of both M0 and M1.
- Discuss the molecular mechanisms and characterization of CRPC.
Practice Gap #2 (Guidelines)
- Discuss specific recommendations within the AUA Clinical Practice Guidelines.
- Define M0 CRPC and the treatment options.
- Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
- Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
Practice Gap #3 (Androgen Axis)
- Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
- Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
- Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
- Discuss new uses for androgen axis agents in M0 CRPC.
Practice Gap #4 (Chemotherapy, Immunotherapy and Co-Morbidity)
- Identify approved chemotherapeutics and immunotherapy for mCRPC.
- Describe indications and contraindications for chemotherapy and immunotherapy in patients with mCRPC.
- Identify co-morbid states and recognize their impact on treatment options for mCRPC.
- Discuss treatment sequencing.
Practice Gap #5 (Bone Health and Radionuclide Therapy)
- Integrate advances in bone health management into patient-specific care plans.
- Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
Practice Gap #6 (Pain Management and Palliative Care)
- Assess and manage pain in patients with CRPC.
- Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
9:00 – 10:00 a.m. Registration & Refreshments
10:00 – 10:10 a.m. Welcome - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
10:10 – 10:25 a.m. Pre-Test - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
10:25 – 10:45 a.m. Initial Management and Imaging of Advanced Prostate Cancer - Todd Matthew Morgan, MD
10:45 – 11:05 a.m. Chemo-hormonal Therapy for Metastatic Hormone Sensitive Prostate Cancer - Alicia Morgans, MD, MPH
11:05 – 11:25 a.m. M0 CRPC: Emerging Treatment Options - Alicia Morgans, MD, MPH
11:25 – 11:45 a.m. MDC and Review of CRPC Guidelines - Michael S. Cookson, MD, FACS
11:45 a.m. – 12:15 p.m. Case Based Roundtable Discussions - Session I - All Faculty
12:15 – 12:20 p.m. Session I Post-Test - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
12:20 – 1:35 p.m. "Elevate Care in Advanced Prostate Cancer"
A Non-CME Lunch Symposium supported by Astellas Pharma US, Inc.
1:35 – 1:55 p.m. Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents -
David F. Jarrard, MD, FACS
1:55 – 2:15 p.m. Radionuclide Therapy and Bone Health - Kelly L. Stratton, MD
2:15 – 2:45 p.m. Case Based Roundtable Discussions – Session II - All Faculty
2:45 – 2:50 p.m. Session II Post-Test - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
2:50 – 3:10 p.m. Break
3:10– 3:40 p.m. Role of Chemotherapy and Performance Status and Pain Management - Robert Dreicer, MD
3:40– 4:00 p.m. Treatment Sequencing, Immunotherapy and Future Approaches - Kelly L. Stratton, MD
4:00 – 4:40 p.m. Case Based Roundtable Discussions - Session III - All Faculty
4:40 – 4:45 p.m. Session III Post-Test - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
4:45 – 5:00 p.m. Closing Remarks - Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
The AUA recommends that you register for the course BEFORE making travel arrangements. Once the meeting capacity is reached, which may be prior to the early-bird date, the AUA is unable to guarantee a spot in the course.
To hold a reservation, a major credit card number must be provided.
$209 single/double occupancy. Reservations can be made by visiting https://www.starwoodmeeting.com/Book/societyofurologic or by calling 1-800-325-3535. Please book your room by October 31, 2018 and reference the Society of Urologic Oncology when making your reservation to receive the special group rate.
Special group rate is subject to availability. After October 31 or once the block is full, the AUA is unable to guarantee rooms at this rate or at this hotel.
Check-in: 3 p.m.
Valet parking is available for hotel guests and visitors for $32 per day. 24-hour self-parking is available for $22 per day. Prices are subject to change.
The Sheraton Grand Phoenix is located approximately 5 miles from Sky Harbor International Airport (PHX). Estimated transportation costs are $22 one-way by taxi and $13 one-way if using the Super Shuttle. Travel time is dependent on time of day and traffic conditions. Additional transportation information and directions.
Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CDP# 1953476.
Michael S. Cookson, MD, MMHC
David F. Jarrard, MD
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this live activity for a maximum of 5.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM.
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
Limit content to evidence with no recommendations
Introduction of a debate format with an unbiased moderator (point-counterpoint)
Inclusion of moderated panel discussion
Publication of a parallel or rebuttal article for an article that is felt to be biased
Limit equipment representatives to providing logistics and operation support only in procedural demonstration.
Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 5.25 AMA PRA Category 1 Credit™
- 5.25 Non-Physician Participation